Torisel (temsirolimus) specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.
Robert Ruffolo, Jr., president of Wyeth Research and senior vice president of Wyeth, said: “The European Commission’s approval of Torisel underscores the importance of this therapy for patients with advanced kidney cancer and reinforces the potential of this mechanism of action as a new approach in oncology.”